Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for Myriad Genetics (MYGN) over the last 14 years, with Q2 2023 value amounting to $6.2 million.

  • Myriad Genetics' Long-Term Investments fell 9210.19% to $6.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.2 million, marking a year-over-year decrease of 9210.19%. This contributed to the annual value of $54.8 million for FY2022, which is 711.86% down from last year.
  • Latest data reveals that Myriad Genetics reported Long-Term Investments of $6.2 million as of Q2 2023, which was down 9210.19% from $30.4 million recorded in Q1 2023.
  • Over the past 5 years, Myriad Genetics' Long-Term Investments peaked at $78.5 million during Q2 2022, and registered a low of $6.2 million during Q2 2023.
  • For the 5-year period, Myriad Genetics' Long-Term Investments averaged around $42.8 million, with its median value being $45.2 million (2020).
  • As far as peak fluctuations go, Myriad Genetics' Long-Term Investments skyrocketed by 49495.8% in 2022, and later plummeted by 9210.19% in 2023.
  • Over the past 5 years, Myriad Genetics' Long-Term Investments (Quarter) stood at $47.6 million in 2019, then tumbled by 55.88% to $21.0 million in 2020, then skyrocketed by 180.95% to $59.0 million in 2021, then dropped by 7.12% to $54.8 million in 2022, then plummeted by 88.69% to $6.2 million in 2023.
  • Its last three reported values are $6.2 million in Q2 2023, $30.4 million for Q1 2023, and $54.8 million during Q4 2022.